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Effect of clonidine on renin release induced by renal artery constriction
in the rat. J. Atkinson, R. Péra-Bally, P. Liithi, and L. Peters-Haefeli.
Institute de Pharmaco/ogie de l'Université, Lausanne, Switzerland. We
have previously shown that renal artery constriction in the uninephrec-
tomized rat induces renin release (an increase in plasma renin level
[PRL}, and a fall in renal cortex renin level [RCRL]), followed by an
increase in blood pressure and drinking. As the centrally acting,
antihypertensive agent clonidine is known to attenuate renin release
and to be antidipsic, we have studied its effects on renin release (and its
consequences) induced by renal artery constriction. Chronically cannu-
lated, 24-hr uninephrectomized female rats, were injected (s.c.) with
0.03,0.1 or 0.3 mg(l.3, 4.35, or 13.0 x l0- moles) clonidine per kg, or
with 0.15 M saline (controls). Thirty minutes later, the remaining renal
artery was constricted (clip: 0.2 mm ID.) under ether anesthesia. Blood
samples and blood pressure recordings were taken via the dorsal aorta
cannula in a conscious rate after recovery from ether anesthesia. The
initial fivefold rise in PRL seen in controls (from 14 3 to 74 14 ng
AImlhr', N = 26), 45 mm after clipping, was abolished by clonidine
at all doses. In clonidine pretreated rats, (preclonidine PRL: 15 3 ng
AIml'hr [results pooled for 3 groups]), there was, however, a
threefold rise in PRL between 3 to 6 hr after clipping, i.e., at a time
when PRL in controls had already fallen to values not significantly
different from preclip values. Thus, clonidine appeared to delay the rise
in PRL provoked by renal artery constriction. Clonidine attenuated the
fall in RCRL following uninephrectomy and clipping, in a dose-
dependent fashion. The comparison of the right clipped kidney with the
untouched left kidney removed 30 hr previously was: controls: —43%,
clonidine: 0.03 mg/kg: —32%, 0.1 mg/kg: —29% and 0.3 mg/kg: — 15%.
These data further confirm our hypothesis that the fall in RCRL
following renal artery clipping is independent of the rise in PRL.
Clonidine, even at the high dose of 0.3 mg/kg, did not block the increase
in blood pressure following renal artery constriction: controls: 117 2
to 142 2 mm Hg at 6 hr after clipping (N = 26), clonidine: 0.3 mg/kg
117 2 to 141 5 mm Hg at 6 hr (N = 10). Clonidine did, however,
block in a dose-dependent manner the dipsogenic response to renal
artery constriction: controls: 29 3 ml H20 kg1 in 6 hr, clonidine:
0.03 mg/kg: 28 4, 0.1 mg/kg, 14 6 and 0.3 mg/kg: 7 1. Clonidine
therefore, modifies the renin release and the dipsogenic response
following renal artery constriction, but does not alter the rise in blood
pressure.
Responsiveness of plasma aldosterone and 18-hydroxycorticosterone to
angiotensin II in essential hypertension, Conn's syndrome, and nontu-
morous hyperaldosteronism. C. Beretta-Piccoli, R. Fraser, J. J. Brown,
A. M. M. Cumming, A. F. Lever, J. J. Morton, andJ. I. S. Robertson.
MRC Blood Pressure Unit, Western infirmary, Glasgow, Scot/and.
Angiotensin II (All) stimulates the secretion of aldosterone (A) and 18-
hydroxycorticosterone (l8-OHB). Since the possibility of an abnormal
adrenal responsiveness to All in hypertensive states is still debated, All
was infused at incremental rates between 0.5 and 8 ng/kg/min into 12
normal subjects, in 10 patients with essential hypertension, in 8 patients
with Conn's syndrome, and in 3 patients with nontumorous hyperaldo-
steronism. Each rate of infusion was maintained for 1 hour, and each
patient received three rates. The plasma levels of All, A, and 18-OHB
were measured before infusion and at the end of each infusion period.
All subjects were studied while taking the same fixed dietary intake of
sodium and potassium. In the 4 study groups the mean preinfusion
plasma All levels did not differ significantly; the plasma A and l8-OHB
tended to be higher in nontumorous hyperaldosteronism than in normal
subjects or essential hypertension (18 2, and 16 4 ng/dl versus 18
I and 7 I ng/dl, or 11 1 and 13 2 ng/dI) and were even higher
in Conn's syndrome (28 9 and 65 14 ng/dI). All infusion increased
the plasma levels of both A and 18-OHB in normal subjects, essential
hypertension, and nontumorous hyperaldosteronism, but did not alter
their concentrations in Conn's syndrome. The steepness of the dose-
response curve relating plasma All to plasma concentrations of A or 18-
OHB was greater in essential hypertension than in normal subjects (an
increase in plasma All of 60 pg/mI induced an increase in plasma A of 23
ng/dl in essential hypertension as compared with 15 ng/dl in normal
subjects. This same difference was present for l8-OHB). The response
of A and 18-OHB to All was also enhanced in nontumorous hyperaldo-
steronism. Thus, the adrenal response to All infused at low doses is
enhanced in essential hypertension and in nontumorous hyperaldoste-
ronism, but is blunted in Conn's syndrome. This and other evidence
suggests that nontumorous hyperaldosteronism is not a variant of
Conn's syndrome, but is indistinguishable from essential hypertension.
Netilmicin in persistent urinary tract infection. F. P. Brunner, G.
Thiel, M. Wenk, and F. Fo//ath. Department of Medicine, University of
Basel, Basel, Switzerland. Netilmicin (NET) was studied in II patients
whose urinary tract infection could not be cured by cotrimoxazole,
aminopenicillins, or other antibiotics. NET (3 or 2 mg/kg) was given
i.m. every 24 to 96 hr (a total of 12 to 6 injections during 3 weeks)
depending on renal function. NET in serum and urine was measured by
radioenzymatic assay. Peak serum NET was 10.6 2.1 and 8.2
1.2 p.g/ml ( SD) with 3 and 2 mg/kg, respectively. Trough
level rarely exceeded I p.g/ml. During treatment, urine NET always
exceeded 4 ig/ml in patients who were not drinking excessively or
receiving furosemide. lndependent of renal function, urinary NET per
mM of creatinine decreased with a t'/2 of7 to 10 days from week 2 to 4
after the last dose of NET and more slowly thereafter resulting in
urinary NET of 2.8 1.5 g/ml after I week and 0.6 0.3 g/ml after 4
weeks. NET cleared infection (followup  12 weeks) in I of 4 patients
with pyelonephritis, 3 of 4 patients with analgesic nephropathy and 2 of
3 renal transplant patients. Despite prolonged urinary NET excretion,
NET-susceptible bacteruria relapsed at 3 to 4 weeks in 3 (2 staghorn
calculi) and at 12 weeks in I patient (renal abscess). One transplanted
patient continued to excrete bacteria sensitive in vitro to NET during
treatment; the infection was shown to originate from her own kidneys
but not from the transplant by retrograde study. Tenacious urinary
infection may be cured with NET using dosage intervals of 24 to 72 hr
even in patients with normal renal function.
Tienilic acid, hyperuricemia, and renal function. A. de Torrente.
Hôpital Communal, La Chaux-de-Fonds, Switzerland. During a 4-
month period (November 1979 to February 1980), ten patients with
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elevated serum uric acid due to diuretic therapy received tienilic acid
(Ticrynafen; T). All these patients were males whose ages ranged from
53 to 76 years. All had a stable cardiovascular function, and none
received known nephrotoxic drugs during T therapy. Eight of these ten
patients sustained a significant impairment of renal function as estimat-
ed by plasma creatinine. Before T, the mean plasma creatinine was 114
17 ji.moles/liter and plasma urate was 626 92 p.moles/liter. One to
six days after T, plasma creatinine was 235 82 mo1es/liter (P <
0,005) and plasma urate was 363 90 ij.moles/liter (P < 0,001). Renal
function returned to pre-T levels in all patients in 4 to 15 days. All
patients were asymptomatic except one who complained of costoverte-
bral tenderness. Urine volumes ranged from 1200 to 2400 mI/day.
Extreme caution should be exercised in administering T to hyperurice-
mic patients because of the significant risk of reversible renal impair-
ment.
Hypotensive effect of the angiotensin-converting enzyme inhibitor cap-
topril in rats with different renin-angiontensin system activities. A.
Essadki, P. Ldthi, N. Boillat, and J. Atkinson. Institut de Pharmacolo-
gie de l'Universite Lausanne, Switzerland. As doubt has arisen whether
the hypotensive effect of captopril is mediated solely by blockade of the
renin-angiotensin system, we have investigated its hypotensive effect in
rats with different plasma and renal cortex renin levels. Different renin
statuses were obtained by left or bilateral nephrectomy in (a) previously
untreated rats (control) or (b) rats whose left renal artery was clipped
for I month (clip 0.2 mm I.D.) prior to nephrectomy. One day after
nephrectomy, all rats were anesthetized with 1.6 g of urethane/kg, i.m.,
the carotid artery and jugular vein were cannulated, 1 mg of atropinel
kg, i.v., was given, and a first blood sample was taken. An i,v. infusion
with a supramaximal dose of captopril (3 mg (1.5 x l0 moles) . kg
min) was started. A second blood sample was taken 10 mm later when
the captopril infusion was stopped. In uninephrectomized control rats
with a renal renin content (RRC) of 1.7 0. 1 mg A! hr (calculated as
renal cortex renin level [ng Al mg hrT'] x [remaining kidney wet
weight (mg) x 0.8], captopril induced a fall in blood pressure of — 30%
(from97 3 to 68 4 mm Hg, N = 9) and stimulated renin release asjudged by an increase in plasma renin level (PRL, in ng Al ml hr')
from 368 82 to 1995 67. In bilaterally nephrectomized controls
(RRC = 0) captopril induced no significant fall in blood pressure. PRL
was at the limit of detection (1.3 0.8) and did not increase following
captopril. After I month of renal artery clipping, renal renin is concen-
trated in the left clipped kidney and depleted in the right kidney.
Removal of the left clipped kidney produces, therefore, a renin-
depleted rat with a RRC (right kidney) of 0.3 0.03 and a PRL of 175
36. In spite of this decrease in both the renal and the plasma renin
levels, captopril induced a significant fall in blood pressure from 84 4
to 70 3 (— 17%), but no significant change in PRL. Removal of both
kidneys from a previously clipped rat, produced even lower renin levels
(RRC = 0; PRL = 4.3 1.4) but again captopril induced a significant
fall in blood pressure (— 23%) with no increase in PRL. These results
raise three possibilities: (1) captopril acts via blockade of the plasmal
renal renin-angiotensin system but the use of a supramaximal dose
masks any correlations between changes in the activity of this system
and the hypotensive effect, (2) captopril acts via blockade of another
renin-angiotensin system, (3) captopril acts elsewhere.
Interaction of renal prostaglandins with diuretics in man. L. Favre, P.
Glasson, B. Dale, and M. B. Vallotton. Division d'Endocrinologie,
Hôpital Cantonal, Genève, Switzerland, To determine if the natriuretic
mechanism of diuretics is mediated by prostaglandins (PG), we com-
pared four drugs acting at different sites: furosemide (F), hydrochioro-
thiazide (HCTZ), triamterene (TMT), and spironolactone (S). In study
A, 22 normal subjects were given orally one diuretic (F, 80 mg; HCTZ,
100mg; TMT, 200 mg; S, 300 mg) for 3 days. In study B, they received
the same diuretic after pretreatment with indomethacin (1DM) at 150mg
for 3 days, continued during diuretic treatment. Urinary PGE2 and F2,.,
aldosterone (AER), and plasma renin activity (PRA) were measured by
RIA's. Results (mean change on day 3 of diuretic):
F (N = 6) HCTZ (N = 6) TMT (N = 4) S (N = 6)
Cumulative Na balance, mmoles
A —152 —159 —43 —208
B — 36 —177 —22 —105
PGE2IAF25,, ng/day
A + 5/— 5 +881—117 +10261+1064 —1201—186
B —401—72 —541+ 98 + 180/+ 65 — 37/—267
LPRA, ng/ml/iAER, i.g/day
A +11.01+35.1 +6.6/+30.9 +4.8/+14.0 i-9.9I+25.9
B + 2.11+ 9.5 +5.11-i- 13.7 +4.31+ 8.9 +0.9/— 2.5
TMT combined with 1DM led to transient renal failure in 2 subjects with
initially normal function. Conclusion, (1) F or S do not modify PG
excretion, but their natriuretic effect is reduced by 1DM, suggesting PG
mediation. (2)Nointeraction is found between HCTZ and 1DM, making
PG mediation unlikely. (3)TMT is a potent PG releaser. Its concomitant
use with 1DM may be nephrotoxic, suggesting a protective role of PG
response. (4) The renin-angiotensin-aldosterone system is made hypo-
responsive to each diuretic by PG inhibition.
Plasma exchange in the treatment of acute renal allograft rejection. J.
Gmür, H. Heule, G. Keusch, A.V. Felten, J. Briner, F. Largiader, U.
Binswanger. Medizinische und Chirurgische Klinik A und Institut fur
Pathologie, Universitatsspital Zurich, Switzerland. Plasma exchanges(PA) were performed to treat 7 acute rejection episodes (ARE) in 6
cadaveric renal transplant recipients occurring 5 to 11 months (5
patients) and 14 years after grafting. All ARE were resistant to
conventional antirejection therapy applied in addition to the usual
immunosuppression with azathioprine and steroids. Biopsy performed
prior to PA in 6 of 7 ARE showed acute vascular rejection in all cases.
Circulating immune complexes (Raji cell assay) were grossly elevated in
3 ARE. The mean serum creatinine of 2.3 (SD) 0.9 mgldl increased to
6.8 0.7 mg/dl within 21 16 days prior to the onset of PA. For PA,
the Haemonetic's model 30 was used. The plasma removed was mostly
replaced by PPF (albumine 4.5%). The mean plasma volume exchanged
was 4250 761 mI/PA or 24.1 11.5 liters/ARE within 10.3 5.6
days. The response to PA was as follows: In 5 of the 7 ARE, the graft
was rejected within 2 weeks after PA treatment, necessitating hemodial-
ysis. In one case, serum creatinine gradually rose from 3.3 mgldl prior
to PA to 7.2 mg/dl within 30 days after PA. In one patient there was a
temporary stabilization of serum creatinine during 2 months, but
thereafter a further ARE occurred, which failed to respond to second
PA treatment. Conclusion. No beneficial long-term effect of PA could
be observed in these 7 acute vascular rejection episodes. Further
investigations are necessary to determine whether plasma exchanges
initiated earlier after onset of ARE and performed more intensively
over a prolonged period of time could be more effective.
Urinary prostaglandins and kallikrein in healthy children from birth to
adolescence. C. M. Godard, B. D. Dale, L. Favre, G. Lucot, H. Favre,
and M. B. Vallotton. Dept. de Pédiatrie, Hôpital de Monthey, et. Div.
d'Endocrinologie, Hôpital Cantonal, Genève, Switzerland. The aim of
this study was to establish normal values for urinary excretion of
prostaglandins (PG) E2 and F2,, and of kallikrein (KALL) at different
ages of development, and to correlate them with several parameters of
renal function. In 58 healthy infants and children of both sexes, aged 2
days to 13 years, daily urinary PGE2 and PGF2,, were determined by
specific radioimmunoassays; KALL was measured by an enzymatic
method. Results (mean sEM) are:
n
Age
1—3 days(N 10) 5—8 days(N = 10)
2—3 weeks
(N = 4)
4—12 months
(N = 7)
4—9 years(N = 14) 10—14 years(N = 10)
POE,, nglday
PGF,.,, ng/day
KALL. mU/day
36.3
134.4
8.2
20.3
04.4
10.7
28.9
161.0
12.0
37.5
231.7
44.8
135.4
625.8
326.3
238.2
710.6
103.1
567.2
±97.!
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In contrast to the activity of the renin-angiotensin-aldosterone system,
which is known to decrease from birth on, urinary PGE2, PGF2C, and
KALL significantly increased with age. These changes were related to
urinary volume and sodium, but after the results had been corrected for
age, surface area, or creatinine excretion, the correlations were obliter-
ated except for KALL. Therefore, the expression used to normalize the
hormone urinary excretion is a determinant in reporting normal values
and proposing physiologic interpretations in children.
Prevention by verapamil of hypoxemia-induced renal vasoconstriction.
J.-P. Guignard, C. Wallimann, and E. Gautier. Service de Pédiatrie,
CHUV, Lausanne, Switzerland. Acute hypoxemia induces renal vaso-
constriction, with consecutive renal hypoperfusion, decreased GFR,
urine output and electrolyte excretion. Experiments were performed in
eight mechanically ventilated anesthetized rabbits to define the nature
of the hypoxemia-induced vasoconstriction. Inulin and PAH clearances
were used as estimates of GFR and effective renal plasma flow (ERPF),
respectively. Acute hypoxemia (arterial P02 = 44 mm Hg) induced a
marked increase in renal vascular resistance, from 4.8 to 11 .8 mm Hg!
ml!kg mm (P < 0.01) and a decrease in GFR from 3.90 to 1,66 (P <
0.001) and in ERPF from 23.2 to 9.3 mi/kg' miii (P < 0.001). Blood
pressure was unchanged. Plasma renin activity increased from a control
level of 25 to 109 ng/ml/hr (P < 0.001) in the hour after induction of
hypoxemia. Verapamil, a potent inhibitor of transcellular calcium ion
transport, which has been shown to prevent the effect of angiotensin II
on the glomerular circulation, was administered to ten rabbits during
normoxemia and hypoxemia. Verapamil administration, 1.0 g/
kg mm, did not change renal function during normoxemia. The effect
of hypoxemia (arterial P02 45 mm Hg) was completely prevented by
verapamil, and there was no significant change in blood pressure, urine
flow, GFR, ERPF, and electrolyte excretion. Renal vascular resistance
remained unchanged at 4.7 during normoxemia and 4.6 mm Hg/mI!
kg mm during hypoxemia. It is concluded that angiotensin II plays an
important role in the hypoxemia-induced vasoconstriction, and that its
effect can be prevented by verapamil administration.
Cardiovascular diseases after kidney allotransplantation: Analysis of
predisposing factors. H. Heule, G. Keusch, U. Binswanger. Nephrolo-
gische Station, Medizinische Klinik, Universit/itsspital, Zurich, Swit-
zerland. Out of 583 patients exhibiting cardiovascular complications
(coronary artery disease, cerebrovascular accident, aneurysma of the
arota, peripheral arterial occlusions) 36 recipients of kidney allotrans-
plants were compared with age- and sex-matched patients without
cardiovascular problems. The following significant differences were
established (study group vs. controls, SD): The systolic mean blood
pressure amounted to 148 31 vs. 134 16mm Hg, the mean diastolic
blood pressure was 93 14 vs. 87 11 mm Hg, both values evaluated
I to 12 years after kidney transplantation. The duration of hypertension
before renal allografting was 1 to 30 years (mean, 9.0), and 0 to 20 years
(mean, 5.7), respectively. Left ventricular hypertrophy was more often
observed: 20/30 vs. 6/32 for ECG signs and 24/33 vs. 13/32 for
cardiomegaly on chest x-ray films. Differences of serum concentrations
included cholesterin (260 69 vs. 225 43 mg/dl), triglycerides (226
112 vs. 178 67 mgldl) and uric acid (6.4 2.0 vs. 5.4 1.2 mg/dl). Of
the study group, 16 patients (but none of the controls) suffered from
cardiovascular disease already present during hemodialysis treatment.
No differences were shown between the two groups for smoking habits,
overweight, hyperparathyroidism, duration of hemodialysis treatment,
and type of kidney disease. The occurrence of diabetes mellitus, the
family history of cardiovascular complications, and hypertonic alter-
ations of the eye fundus were more frequent but not statistically
different in the study group as compared to control patients. These data
stress the need for regulation of blood pressure, hyperlipemia, and
hyperuricemia in view of successful long-term rehabilitation after
kidney allografting.
Effect of aldosterone on urinary excretion of lithium in the adrenalecto-
mized rat. J. D. Horisberger and J. Diezi. Institut de Pharmacologie,
Université de Lausanne, Switzerland. Lithium (Li) is reabsorbed in the
proximal tubule in parallel with sodium. Micropuncture studies have
shown no transepithelial movements of Li beyond the 1oop of Henle.
Diuretics acting on the proximal tubule enhance urinary excertion of Li.
"Loop" diuretics and distally acting diuretics diminish the excretion of
Li after chronic administration, but have no or little effect in acute
experiments. We studied the effect of a physiologic dose of aldosterone
in the adrenalectomized rat, in conditions where its antinatriuretic and
kaliuretic effects are pronounced. Male Wistar rats are adrenalecto-
mized. Twenty-four hours later, they were anesthetized with mactin
and received iv. low-dose glucocorticoid substitution (plasma level of
dexamethasone maintained around 5 nM). An isotonic solution contain-
ing Na (55 mEq/liter), Li (15 mEq/liter), K (4 mEq/liter) and glucose was
continuously infused at a rate of 0.360 mI/kg/mu. After 150 mm of
equilibration, aldosterone (or the solvent in control group) was adminis-
tered at a rate of 1 g!kg/hr, following a loading dose of I g/kg BW.
Nine clearance periods of 30 mm each were performed. Plasma
concentrations of Na, K, and Li, urinary volume, blood pressure and
GFR were similar and steady in the two groups. In control group (N =
5), FEN8, FEK, and FELl remained nearly constant. In the treated group
(N = 6), FEN8 fell from 2.3% (first clearance period, similar to control)
to 0.5% (last clearance period, p < 0.001 when compared to control
group); FEK rose from 12% (first clearance period, similar to control) to
31% (last period, p <.01 when compared to control). In the two groups,
FEL remained constant around 29% in all periods. These results show
that, when administered acutely, aldosterone has no effect on the
urinary excretion of Li. The previously reported effects of long-term
DOCA or spironolactone administration on Li excretion are probably
secondary to modifications of the sodium balance which, in turn,
influences the proximal ion and fluid reabsorbtion rate.
Urinary kinin excretion in patients with essential hypertension as
compared with normal subjects. U. L. Hulthén. Division of Cardiology,
Department of Internal Medicine, Kantonsspital, Basel, Switzerland.
The renal kallikrein-kinin system has been implicated as a physiologic
factor promoting renal vasodilatation and natriuresis. Generally, uri-
nary kallikrein excretion (UK8) has been taken as an index of the
activity of the renal kallikrein-kinin system. In patients with essential
hypertension (EH), lower UK8 as compared to normal subjects (N) has
been reported and suggested to represent a primary pathophysiological
disturbance. Urinary kinins are also of renal origin, and the urinary
excretion of kinins (UKI) most likely reflects the intrarenal generation of
kinins. UKI, determined by radioimmunoassay as bradykinin equiva-
lents (Bk-Eq), and urinary sodium excretion (UNa) were measured in
24-hr urine collected from 21 patients with EH with normal renal
function (17 men and 4 women, aged 22 to 65 years) and 50 N (21 men
and 29 women, aged 23 to 72 years). No significant difference in UKI
was found between EH (44.4 [SD] 21.7 g Bk-Eq/day) and N (42.3
15.3 Bk-Eq/day). UN8 was also similar to the two groups, 140 77
mmoles/day in EH and 147 60 mmoles/day in N. There was a positive
correlation between UKI and UNa in EH (r = 0.46; P < 0.05) as well as
in N (r = 0.48; P < 0.001). The finding of unchanged UKI in EH as
compared to N do not support a primary disturbance of the renal
kallikrein-kinin system in EH and tallies with recent studies showing a
reduction of UKa in EH only when renal function is impaired. The direct
relationship between UKI and UN8 in both groups support the concept
that intrarenal formation of kinins is implicated in the regulation of
natriuresis.
Pitfalls in diagnosis and treatment of idiopathic hypercalciuria. P.
Jaeger and P. Burckhardt. University Hospital, Lausanne, Switzer-
land. Pitfalls in the diagnosis and treatment of idiopathic hypercalciuria
(IH) are becoming apparent and will be described on the basis of our
experience of 73 patients with urolithiasis. (1) Renal IH (RH) is
assessed either with the calcium-creatinine (Calcreat) ratio in the fasting
urine, or with 24-hr U8V measured during a low calcium diet. In 4 out
of 32 cases, the difference between the fasting Calcreat ratio measured
after a normal diet and that after a calcium-enriched diet exceeded the
variability of this parameter determined in 35 cases examined twice
under stable diet. Therefore, the diet of the preceding day can influence
the fasting Ca/creat ratio. (2) IH can be investigated with a protocol
either for ambulatory or for hospitalized patients; the latter is generally
shorter, includes a single calcium load and uses the fasting Ca/creat
ratio as the major criterion for a renal leak of calcium. We compared
both methods on 55 outpatients and 27 inpatients with urolithiasis. It
appeared that our inpatient protocol underestimated the frequency of
calcium hyperabsorption. (3) Secondary hyperparathyroidism (HP) has
been claimed to be a diagnostic criterion for RH. We tested the
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parathyroid function of 33 patients with RH, using PTH determinations
in various conditions, such as changes in the calcium content of the
diet, EDTA infusions, and chlorthalidone (CT) administration (100 mgI
day for 4 weeks). HP has not been found in any of the cases. (4) CT
reduces calciuria via an increment in TRca. A significant correlation
was observed between UcaV and UNaV under CT in 13 patients (y =
2.4 x —233, r = 0.90, P < 0.001); in the 5 of them who had a natriuresis
higher than 200 mEq/day, calciuria did not become normal. (5) Finally,
dietetic peculiarities of some patients (spontaneous cutdown on milk
products, consumption of water with unexpectedly high calcium con-
tent) having led to erroneous diagnosis will be illustrated. Conclusion.
Diagnosis of RH can be missed if one uses the fasting Ca/creat ratio of
PTH level as diagnostic criteria, calcium hyperabsorption can be
overlooked with short protocols, and CT treatment fails in case of
excessive sodium intake.
Effect of continuous ambulatory peritoneal dialysis on lipoprotein
metabolism. G. Keusch, F. Bammatter, R. Mordasini, H. Heule, U.
Binswanger. Nephrologische Station, Universitatsspital Zurich und
Tiefenauspital, Bern, Switzerland. In a prospective evaluation, serum
lipids and lipoprotein profiles were analyzed in 21 patients (pts.) (9
male, 12 female) with a mean age of 49. 1 (sEM) 2.6 years prior to
CAPD and sequentially at 1, 3, and 6 monthly intervals during CAPD
treatment. The lipoprotein fractions were isolated by sequential ultra-
centrifugation, and the analyses were performed according to the Lipid
Research Clinic Program. Serum cholesterol, triglycerides, very-low-
density-lipoprotein cholesterol (VLDL-C), LDL-C, high-density-lipo-
protein cholesterol (HDL-C), and the LDL-C/HDL-C ratio did not
change significantly during CAPD treatment. The means SEM were as
follows:
Pre-CAPD
(N I3)
Months of treatment
(N = 14) (N II) (N = 12)
Cholesterol, mgldl
Triglyceride, mg/d!
246 18
178 13
261 15
207 25
288
156
28
20
271
237
26
62
VLDL-C, mg/dI 44 6 48 6 45 14 60 22
LDL-C, mg/dl 154 13 145 10 152 19 148 25
HDL-C, mg/dI 33 22 45 4 47 3 36 3
LDL/HDL-C 4.8 0.4 3.8 0.4 3.5 0.5 4.5 0.8
There was a positive correlation between loss in the peritoneal effluent
and serum concentrations for cholesterol (r = 0.52; P < 0.001) and
triglycerides (r = 0.60; P < 0.001). Nine pts. had a normal lipoprotein
profiles prior and during CAPD treatment; 4 pts. changed from a normal
to an abnormal profile (lilA, 3 IIB, Fredrickson classification) and in 8
pts. the abnormal profile (3 hA, 3 lIB, 2 IV) had not changed during
CAPD treatment. Five of six pts., in whom arteriosclerotic complica-
tions occurred during CAPD treatment, had an abnormal lipoprotein
pattern. Conclusion. An abnormal lipoprotein profile may develop
during CAPD or an abnormal profile prior to CAPD may persist despite
adequate control of uremia and contribute to an increased incidence of
arteriosclerotic complications.
Reversal or prevention of diuretic-induced alterations in serum lipopro-
teins with betablockers. A. Meier, P. Weidmann, R. Mordasini, W.
Riesen, and C. Bachmann. Medizinische Poliklinik, Institute for Pro-
tein Research and Department of Clinical Chemistry, University of
Bern, Switzerland. Previous studies in this laboratory demonstrated
that some diuretics may increase serum low-density-lipoprotein choles-
terol (LDL-C). Others reported that betablockers (B) may decrease
LDL or high-density-lipoprotein cholesterol (HDL-C). Since combina-
tion treatment with diuretics and B is a common therapeutic approach
in hypertension, we evaluated possible interactions between the effects
of the two classes of drugs on lipoprotein metabolism in 18 patients with
essential hypertension (mean age, 44 (sEM) 3 yr). Compared to
placebo (P) conditions, LDL-C (measured by ultracentnfugation meth-
od) was significantly (P < 0.001) increased following short-term therapy
with chlorthalidone (Ch), 100 mg/day, but not during combination
therapy with Ch and B (propranolol, 120 to 480 mg/day, in 14 patients;
atenolol, 100 mg/day, in 3; and oxprenolol, 320 mg/day, in I case). This
tendency was similar in two subgroups which were studied with an
inverse sequence of drug adminstration. In group I (II men), a 22%
increase (P < 0.01) in LDL-C following 6 weeks of Ch monotherapy
was restored to normal 6 weeks after addition of B to Ch. In group 2 (5
men, 2 postmenopausal women) LDL-C was comparable to P condi-
tiOns after 14 3 weeks of Ch-B combination therapy, but was
increased by 41% (P < 0.05) 6 weeks after withdrawal of B. No
significant changes occurred during either treatment phase in total
cholesterol, triglyzeride, HDL-C or apoprotein B (measured by radial
immunodiffusion) levels. It is concluded that combination therapy with
B may prevent or reverse an increase in serum LDL-C associated with
short-term Ch monotherapy.
All Group I Group 2
LDL-C, mg/dl
P 105 7 109 11 99 8
Ch 135 l0 131 14** 140 11*
Ch-B 109 9 112 9 105 19
HDL-C, mg/dl
P 50± 3 55± 4 42± 4
Ch 47± 3 48± 3 44± 5
Ch-B 44± 3 48± 3 38± 5
* P < 0.05; ** < 0.01; P < 0.001 vs. placebo.
Comparison of the effect of furosemide and piretanide (HOE 118) on
arachidonic acid and prostaglandin release from human fibroblasts in
culture. F. Mestel, U. Stucki, and 0. Oetliker. Department of Nephrol-
ogy, Universitatskinderklinik Berne, Berne, Switzerland. Both drugs
arecomparable "high ceiling diuretics". '4C-arachidonic acid ('4C-AA)
(diluted with at least a 1000-fold excess of cold AA) was allowed to
equilibrate with the fibroblast monolayers. The drugs were adminis-
tered simultaneously with bradykinin (BK), 1 hour or 24 hr prior to BK
stimulation. Released radioactivity was analyzed by thin-layer chroma-
tography after ether extraction of the media. Two different procedures
were investigated in each culture dish: (1) the influence of the drug on
the incorporation and the concomitant release of label and (2) the
remaining effect on BK-induced release of PG's after removal and
washout of the drug. Within 5 mm, furosemide (F) as well as HOE 118
neither stimulated the release of AA or its metabolites nor potentiated
the BK-induced release into buffer. Incubation of the drugs in growth
medium for 1 hr induced a 4 to 5-fold increase of free AA and no
significant effect on PG's. Subsequent stimulation with BK yielded an
increased AA release, as well. Whereas F increased 6-oxo-PGF1,,
(representative for prostacyclin) and PGE2, almost 2-fold, HOE 118 did
not elevate the PG-response to BK. During the 24-hr incubation, free
AA was doubled, 6-oxo-PGF1,, and PGE2 were elevated 1.5-fold by F,
whereas no increase was seen after HOE 118. The difference between
the action of F and HOE 118 was most pronounced in the response to
BK after 24-hr pretreatment with the drugs. After F, AA was 3-fold
higher, 6-oxo-PGF1, and PGE2 were increased 3.5- and 2.5-fold,
respectively. HOE 118 did not influence the release of AA and the
formation of PG's. F, known to stimulate PG synthesis, does not exert
the same effect in cultured human fibroblasts as does bradykinin, since
F fails to stimulate PG's within 5 mm. Although some spontaneous PG-
production was seen after 1 and 24 hr of incubation with F, this drug
exerts its most dramatic effect by potentiating the bradykinin response,
possibly by changing the reactivity to this phospholipase stimulator. A
similar effect of Hoechst 118 was seen only after 1 hr of incubation, thus
exerting at most a transient effect.
Interstitial nephritis accompanying glomerulonephritis: Frequency,
morphology, functional, and prognostic significance. M. J. Mihatsch, J.
Torljorst, U. Straumann, M. Oberholzer, H. U. Zollinger. Institut für
Pat hologie der Universitdt Basel, SchOnbeinstr. 40, Basel, Switzerland.
(1) Four hundred sixty unselected biopsies in glomerulonephritis (GN)
were semiquantitatively evaluated. No interstitial nephritis (IN) was
found in 58% (69% excluding cases of glomerular minimal change). IN
was medium or severe in 21% (28.5%). The most severe forms of IN
were found in extracapillary accentuated GN, the least severe in
glomerular minimal change, endotheliomesangial GN, and epimem-
branous GN. The interstitial infiltrate is composed of lymphocytes,
plasma cells, and histiocytes in 70% of cases, in an additional 30% of the
cases, eosinophilic and/or neutrophilic leukocytes and/or lymphfollicles
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were present. (2) One hundred forty-six GN-biopsies were morphomet-
rically investigated. Serum creatinine (serum urea, creatinine clear-
ance) is negatively influenced by the interstitial enlargement (fibrosis)(Kendall-test, P < 0.01). Glomerular parameters (glomerular obsoles-
cence, mesangial enlargement) are of additional importance. PAH
clearance is mainly influenced by the number of obsolescent glomeruli
(Kendall test, P < 0.01). Furthermore, there is a significant positive
correlation between blood pressure on the one hand and interstitial
enlargement and obsolescent glomeruli on the other (Kendall test, P <
0.01). (3) Based on 200 unselected cases of GN, there is a significant
correlation between the severity of IN and the 5-year survival rate: 88%
survival rate in patients without or with slight IN, 42% in those with
medium or severe IN. There is a better correlation between IN and
survival rate than there is with the GN type.
Prevention of peritonitis in continuous ambulatory peritoneal dialysis.
M. Oliveri and K. Záruba. Nierenstation, Stadtspital Waid Zurich,
Switzerland. Continuous ambulatory peritoneal dialysis (CAPD) is a
promising method for the management of chronic renal failure. The
most frequent complication of CAPD is peritonitis, especially in older
patients and patients with reduced defence ability. Although the inci-
dence of peritonitis has been reduced by improvement in CAPD
systems, the problem is not yet adequately solved. We have been
concerned with the possibility of preventing microbial invasion of the
peritoneal cavity as well as early detection of peritoneal infection. We
have thus developed two new methods for peritonitis prevention: (1)
The dialysate-bag exchange is done in a small basin under a layer of
disinfectant solution (0.1% Chlorhexidine). (2) The patients check the
dialysate-drainage daily for infection, using a simple method: Twice a
day, during dialysate exchange, mornings and evenings, they transfer 5
ml of dialysate drainage into a nutrient medium tube using sterile
technique. The dialysate-digest-medium-tube (DDM-tube) is then incu-
bated in a small incubator at 370 C. The patients check the DDM-tubes
themselves every 12 hours for 2 days. A cloudy tube indicates the
presence of bacteria, and in such a case the patient reports immediately
to the dialysis center. Intraperitoneal antibiotics are then added to the
dialysate immediately to prevent the onset of peritonitis. Cultures of the
dialysate drainage are inoculated before the antibiotics are started to
confirm the diagnosis of pentoneal infection without peritonitis. Simul-
taneously, a sensitivity plate is inoculated, so that sensitivity reports
are available the next day. If culture of the last drainage before starting
antibiotics is positive, the therapy is continued for a further 6 days, and
adjusted to the sensitivity reports. If the culture is negative, antibiotics
are stopped. In our experience both methods can successfully be used
in prevention of the peritonitis in CAPD.
Measurement of renal kallikrein during the development of renovascu-
lar hypertension. B. Rastetter, G. Bonner, M. Marin-Grez, and F.
Gross. Department of Pharmacology, University of Heidelberg, West-
Germany. It has been suggested that renal kallikrein might be involved
in the development of renal hypertension. To test the validity of this
hypothesis, we measured renal kallikrein in rats made hypertensive by
constricting the left renal artery with a silver clip and removing the
contralateral kidney (1K1C) or leaving the other kidney untouched
(2K1C). Control rats underwent a similar operation except that no clip
was implanted. Blood pressure (BP) was measured plethysmographical-
ly, and kallikrein was measured by incubating renal homogenates with a
synthetic tripeptide substrate. Results are expressed as means SEM.
Kallikrein is given in mu/mg of protein.
Control 2KIC
Control IKIC
LK LK RK LK RK LK
Kal. mU/mg 0.36 0.36 0.46 0.52 0.39 1.720*
BP (3rd day), mm Hg 104.00
(N = 8)
137.08°°
(N 8)
96.43
(N 7)
I l5.7I°
(N = 7)
Kal, mU/tng 0.22 0.16 0.34 0,33 0.21* 0.17*
BP(ltthday),mmHg 92.25
(N = 8)
130.29°°
(N = 7)
101.43
1.32
(N — 7)
145.71*0
(N = 7)
*P < 0.05;** P < 0,005 (experimental vs. control).
BP was already increased by the 3rd day of clipping in the 2KIC model;
at this time, renal kallikrein was high in the clipped and unaffected in
the unclipped kidney. Thus, it appears that this vasodepressor enzyme
is not involved in the development of hypertension in this model. It
appears to be the same for the IK1C model.
Dialysis treatment of acute chromium intoxication, and comparative
efficacy of peritoneal versus hemodialysis in chromium removal. H.
Schiffi, M. Weiss, P. Weidmann, and S. G. Massry. Med. Poliklinik,
Univ. of Berne, and Div. of Nephrol, Univ. of Southern California, Los
Angeles. External burnings with chromic acid have been fatal even in
cases with corrosions covering less than 10% of body surface area. We
observed a 19-yr-old man with third degree burns and chromium (Cr)-
intoxication following accidental contact of both legs with a Cr acid
solution. The initial course was characterized by serum Cr levels known
to be usually lethal (2.2 mg/liter), complete anuria, hepatic damage, and
progressive anemia. Aggressive peritoneal dialysis (PD) with a total
duration of 252 hr between the 4th and 22nd day after exposure caused a
progressive decrease in serum Cr levels and resulted in a complete
recovery after 36 days. This clinical case was an important argument to
evaluate the comparative efficacy of PD versus hemodialysis (HD) in Cr
removal. Following iv. injection of 500 i.Ci of 51CrCl3, 4 to 10 serial
measurements of Cr clearance were performed in patients with terminal
renal failure. Cr clearance derived by standard methodology averaged
0.8 0.3 mI/mm in 5 patients treated with PD and 2.5 0.8 mI/mm in 6
treated with HD. It is concluded that HD is about three times as
effective as PD in Cr removal per unit of time. However, the possibility
to apply uninterrupted PD during the first few days suggests that this
method is at least equivalent to HD for treatment in the initial stage of
Cr intoxication.
Renal hemodynamics and autoregulation in old age. F. Schneider and
B. Truniger. Medizinische Klinik, Kantonsspital, Luzern, Switzerland.
Mean renal blood flow (RBF) was measured on the basis of the initial
slope of '33xenon washout curves, and renal vascular resistances were
calculated in 18 young, adult (mean age, 25.7 0.1 weeks) and 10 old
(age, 102 0.2 weeks) albino rats. Experiments were performed in
Nembutal anesthesia. The renal perfusion pressure was lowered in
steps of 10 mm Hg down to 60 mm Hg by means of an adjustable aortic
clamp placed below the diaphragm and above the renal arteries. At a
perfusion pressure of 110 mm Hg, the young rats showed a mean RBF
of 3.52 (SD) 1.04 ml/min'g of kidney wt and a renal vascular
resistance of 32.51 10.50mm Hg/ml/min/g of kidney wt. Both values
were significantly different from those observed in old animals, which
showed a mean RBF of 2.85 0.99 ml/min'g and a renal vascular
resistance of 41.18 14.74mm Hg/ml/min/g of kidney wt. Young adult
rats perfectly autoregulated their RBF down to 100mm Hg by lowering
the renal vascular resistance. In agreement with previous observations,
a further decrease in vascular resistance at perfusion pressures < 100
mm Hg did not prevent a pressure-dependent decrease in RBF. In
contrast, in old animals RBF at perfusion pressures < 120 mm Hg was
strictly pressure-dependent, and no autoregulatory changes in renal
vascular resistance were observed. After releasing the aortic clamp, 5
old and 7 young rats showed a similar, sharp increase in renal vascular
resistance from 99.9 6.4% to 134.3 15.1% in old, and from 84.1
14.6% to 141.3 31.5% in young animals, the renal vascular resistance
measured at a perfusion pressure of 110 mm Hg being taken as 100%. It
is concluded that in old rats an increased basal renal vascular resistance
cannot be lowered by autoregulatory mechanisms. It may, however, be
further increased by various stimuli.
Renal toxicity of cyclosporine A in the rat. G. Thiel, D. de Rougemont,
J. Torhorst, and F. P. Brunner. Departments of Internal Medicine and
Pathology, University of Basel, Switzerland. Impaired renal function
and tubulointerstitial pathology have been observed in patients under-
going long-term treatment with the potent immunosuppressant cyclo-
sporine (CYCLO). Acute renal toxicity of CYCLO has been suspected
in cadaveric transplants. To see whether CYCLO would potentiate
ischemic renal injury, we studied two groups of uninephrectomized rats
receiving 20 or 50 mglkg/day CYCLO in olive oil by gavage. Half of the
rats in each group and a control group on olive oil were subjected to 90
mm of clamping of the remaining left renal artery, and all rats were
placed in metabolic cages. Ten rats in each group were bled and killed 2,
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4, and 8 days after starting CYCLO, with or without renal ischemia.
Blood urea (mg/dl SEM) at sacrifice was:
Isehemia No ischemia lschemia No ischemia lschemia
Day 2 52 -'- 2 97 16 48 -'- 2 190 42
Day4 48±2 59± 2 40±4 63± 10
Day8 59*4 55-- 3 71±6 65± 5
2 rats died on day 5 and I on day 6 and 8
Food intake was poor, and urea excretion progressively decreased in
CYCLO-treated rats. However, BU rose in CYCLO-treated rats with-
out ischemia, and 24-hr creatinine clearance fell to 1/2 to 1/3 of control
on day 8 in the 50-mg/kg CYCLO group. CYCLO aggravated ischemic
acute renal failure, but this aggravation appeared reversible. Histologic
changes due to ischemic injury were similar in CYCLO-treated and
control rats.
Does captopril prevent renal failure in scleroderma? J. P. Wauters, H.
R. Brunner, and B. Waeber. University Hospital, Lausanne, Switzer-
land. Renal failure in progressive systemic sclerosis (PSS) is most often
due to malignant nephroangiosclerosis initiated by stimulation of the
reninangiotensin system. It has been claimed that an increase in plasma
renin activity (PRA) forecasts the renal crisis and that chronic blockade
of the angiotensin converting enzyme by captopril could prevent the
deterioration of renal function. Three patients with PSS, age 46, 60, and
57 years, were hospitalized with a blood pressure of 160/1 10, 200/100,
and 180/90mm Hg, plasma renin activity of 19.4, 11.5, and 16.6 ng/ml/
hr, and serum creatinine levels of 274, 565, and 884 p.moles/liter,
respectively. Captopril was started at the dose of 100 mg p.o. twice a
day. In all patients, sustained control of blood pressure at 120/80 mm
Hg was obtained immediately. Renal function, however, deteriorated
further, and hemodialysis had to be started 1, 4, and 7 weeks after
captopril was initiated. Despite the control of uremia by hemodialysis
and blood pressure by captopril, patients did not improve clinically. All
3 died of respiratory failure after 3, 8, and 4 weeks, respectively, of
hemodialysis. This course is in contrast with that of another female
patient of 48 years, with PSS, malignant hypertension, and terminal
renal failure. Chronic hemodialysis and antihypertensive therapy with
sodium nitroprusside and subsequently beta-blockade were instituted.
Twenty months later, due to recovery of renal function, hemodialysis
could be discontinued; 3 years later serum creatinine is at 275 p.moles/
liter. Conclusions. In patients with PSS: (1) chronic blockade of the
renin-angiotensin system by captopril, despite blood pressure control,
does not always prevent the deterioration of renal function. This
suggests that the renin-angiotensin system is not the sole factor leading
to renal failure. (2) On the other hand, even in the face of advanced
renal failure, spontaneous improvement of kidney function can occur.
Therefore, bilateral nephrectomy should be avoided.
Massive fluid retention with pericardial effusion in minoxidil treatment.
K. Záruba, M. Rohacek, W. Grauer. Nierenstation u.Inst.f.Rontgen-
diagnostik Stadtspital Waid Zurich, Switzerland. Minoxidil, a piperi-
dino-pyrimidine derivative, is one of the most effective hypotensive
drugs. It is particularly suitable for the treatment of refractory hyper-
tension and can successfully be instituted in patients with end-stage
renal failure. The drug's direct effect on arteriolar smooth muscle
causes peripheral vasodilatation. Minoxidil, like other vasodilator
drugs, induces a marked tendency to sodium and fluid retention,
consecutive to increased sodium reabsorption in the proximal tubule. A
45-year-old patient with chronic glomerulonephritis was treated with
minoxidil for severe hypertension during the year preceding the start of
hemodialysis. He developed severe fluid retention in spite of simulta-
neous treatment with furosemid and diuresis > 2 liters in 24 hours. On
admission for hemodialysis in our center, there was extensive edema;
X-rays and echocardiography showed a massive pericardial effusion.
With forced ultrafiltration-hemodialysis (UF-HD), we succeeded in
reducing the body weight by 17 kg within 4 weeks. During this time the
peripheral edema as well as the pericardial effusion were gradually
reabsorbed, and the blood pressure returned to normal without the use
of hypotensive drugs. Patients on minoxidil, especially those with renal
failure, should regularly be checked for fluid retention and pericardial
effusion. Early increase in diuretic therapy or institution of UF-HD in
end-stage renal failure can prevent the formation of a potentially
dangerous pericardial effusion.
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Subcutaneous heparin therapy in renal insufficiency. K. Andrassy, W.
Salzmann, J. Bommer, and J. Koderisch. Medizinische Universitäts-
klinik Heidelberg, FRG. It is often necessary to treat uremic patients
with low doses of heparin, for example, for prophylaxis or Cimino-
fistula thrombosis. However, little information is available on heparin
pharmacokinetics and heparin action in uremic patients. In the present
study, plasma activity-time profiles during low-dose heparin therapy
were investigated in control individuals and in uremic patients. Meth-
ods. Heparin levels at 0, 3, 8, 10, 12, 24, 27, 32, 34, and 36 hr after s.c.
injection of various doses of heparin (2 x 7, 500 I.U./day for 2 days, 3
x 5,000 I.U. for 2 days and 2 x 5,000 I.U. for 2 days) were measured in
9 control individuals and in 11 uremic patients (Ce. < 10 mI/mm).
Heparin activity was determined by measurements of (1) neutralization
of factor Xa-activity (Denson and Bonnar); (2) neutralization of Xa
measuring amidolytic activity (Teien and Lie); (3) plasma prothrombin
and thrombin time. Heparin-cofactor concentrations were measured
with immunodiffusion and by measuring amidolytic activity. Results.
With the dose of 2 x 5,000 I.U. of heparin s.c., no difference between
control individuals and uremic individuals was found. In contrast, peak
concentrations of heparin were significantly lower in uremic patients
after 7,500 I.U. heparin s.c. After repeated administration of heparin,
trough concentration (24 hr) had fallen to 0 in uremic patients, whereas
in controls, a measurable residual activity was still demonstrable. The
difference between uremic patients and control individuals was particu-
larly marked at higher doses. Conclusion. The results show that to
reach a given profile of heparin activity, higher s.c. doses of heparin
must be administered in uremic patients than in nonuremic control
persons.
Reversible resistance to the phosphaturic effect of parathyroid hormone
and db-cAMP in lithium-treated rats. S. Angielski, K. Drewnowska, M.
Szczepaiiska-Konkel, and A. Rybczyiska. Department of Clinical Bio-
chemistry, Institute of Pathology, Medical Academy Gdañsk, Poland.
It has been shown that acute lithium (Li) administration to rats induces
extracellular acidosis, probably due to the transport of Li into the cells
as LiCO3 with consequent and perhaps organ-selective alkalinization of
the intracellular space. Unresponsiveness to the phosphaturic effect of
parathormone (PTH) and db-cAMP in parathyroidectomized (PTX) Li-
control 20mg CYCLO 50mg CYCLO
No ischemia
36 2
43 + 3
70 7
Ischemta
208 * 50
58 * 9
70 ±
